Antitumor agent-88, a competitive inhibitor of CYP1A1 (K i: 1.4 μM), demonstrates significant antimitotic activity by arresting cells in the G2/M phase and disrupting the microtubule network and cytoskeleton in CYP1A1-expressing breast cancer cells.